Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| High selective OX1R/OX2R dual inhibitor treating insomnia | Small molecule | Neurological disease | Insomnia | Phase I | Global |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| CR2-H52H6 | Human | Human CD200 R1 / CRTR2 Protein, His Tag |  |
|
|
| CR2-H82F4 | Human | Biotinylated Human CD200 R1 / CRTR2 Protein, Fc,Avitag™ |  |
|
|
Immobilized Human CD200, Fc Tag (Cat. No. OX2-H5251) at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD200 R1, Fc,Avitag (Cat. No. CR2-H82F4) with a linear range of 0.5-7.8 ng/mL (QC tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| P-006 | 23ME-00610; P-006; 23ME’610 | Phase 2 Clinical | 23andme Inc | Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Carcinoma, Ovarian Epithelial; Neuroendocrine Tumors; Peritoneal Neoplasms; Fallopian Tube Neoplasms | Details |
| Ucenprubart | LY-3454738 | Phase 1 Clinical | Eli Lilly And Company | Chronic Urticaria; Dermatitis, Atopic | Details |
This web search service is supported by Google Inc.
A-Z
